Juva Life Reports Strong Growth in Q3 2023 Financial Results

Juva Life Reports Strong Growth in Q3 2023 Financial Results

Redwood City, California – December 13th, 2023 – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life” or the “Company”), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to announce its financial results for the third quarter ending September 30, 2023.

Key Highlights:

  • Revenue Growth: Juva Life reported a substantial increase in sales, with Q3 2023 sales reaching $3.17 million, compared to $1.25 million for the same period in 2022.
  • Cost Reduction: The company successfully reduced its net loss for Q3 2023 to $782K, a significant improvement compared to a net loss of $2.9 million in Q3 2022.
  • Operational Expansion: The completion of construction and full operational capability at the San Juan Facility in Stockton, California, has contributed to increased cultivation, manufacturing, distribution capacity, and a related increase in revenue.
  • Retail Growth: The addition of a retail store, operational as of June 2023, at the intersection of Broadway and Hamilton streets in Redwood City, CA, has further expanded Juva's presence, complementing its delivery services throughout the Bay Area Peninsula.

Financial Overview:

  • Sales: Sales for the nine months ended September 30, 2023 reached $6.4 million, a 52.3% increase over the $4.2 million in revenue for the same period in 2022.
  • Net Loss: The net loss for the nine months ended September 30, 2023, was $4.2 million, a substantial improvement from the $7.9 million loss in the corresponding period in 2022.

Operational Efficiencies:

  • EBITDA Improvement: Despite the challenges in the industry, Juva Life achieved positive strides in operational efficiencies, with EBITDA improving from a negative $4.97 million in Q3 2022 to negative $141K in Q3 2023.
  • Adjusted Gross Margin: The adjusted gross margin for Q3 2023 reached $1.4 million compared to $377K in the same quarter of the previous year.

Doug Chloupek, CEO and Founder of Juva Life, stated, "We are thrilled to announce our outstanding Q3 results and the successful execution of our strategic initiatives. The robust performance of our Redwood City retail store, coupled with operational achievements in our cultivation and distribution facility, reflects our commitment to innovation and operational excellence."

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company will leverage revenue derived from its retail operations to advance potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 


Juva Life Provides Update on California Cannabis Operations

Juva Life Provides Update on California Cannabis Operations

Redwood City, California – October 3rd, 2023 – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life” or the “Company”), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to provide an update on its thriving cannabis operations. Juva Life’s cannabis operations consist of Cultivation, Distribution and Retail licenses in California currently spread across two facilities.

The Stockton Cultivation and Distribution facility is the backbone of Juva Life's three renowned brands: Frosted Flowers, Flōs, and Secret Sauce. Frosted Flowers, known for its premium-grade cannabis flowers, is set to launch a new cannabis vape category in the coming months. The custom designed glass cartridge will feature Rosin Absolute, which is produced utilizing an FDA and EU approved solvent for food additives.  The Company meticulously integrated this solvent into its extraction methods by using state-of-the-art perfuming technologies not currently employed in the cannabis industry. The benefits of this extraction method included a low-temperature, low-pressure extraction that requires no post-processing. The result is a pure cannabis extract that closely resembles the experience of consuming cannabis flower without the presence of plant matter. Flōs, the Company’s other cannabis flower brand, offers small, premium-grade cannabis flowers at a competitive price point, while Secret Sauce delivers high-grade cannabis concentrates at budget-friendly prices. The company has rapidly expanded distribution of all three brands, securing placements in 110 California retail locations, capturing approximately 13% of the total California cannabis retail market (source: CalMatters).

In related news, Juva Life proudly announces that the Stockton facility is now operating at full capacity after two years of optimization efforts. The facility consistently surpasses industry averages, with top-performing cultivars yielding an impressive 58 to 73 grams per square foot, far exceeding the industry average of 39.5 grams per square foot (source: Cannabis Business Times). In addition, the facility's shift to almost 100% natural gas power generation has resulted in an outstanding 80% reduction in related electricity costs.

Meanwhile, Juva Life's Redwood City retail store, open for just over three months, is experiencing exceptional growth. While many retail stores grapple with declining sales, the Redwood City store is seeing incremental growth and is currently delivering an annualized revenue of over $7 million with a gross margin of 55%.

"As we continue to reach new milestones and set industry standards, Juva Life is thrilled to announce our latest achievements in the thriving cannabis sector,” said Doug Chloupek, Juva Life’s CEO. “Our unwavering commitment to innovation, quality, and operational excellence has allowed us to not only meet but exceed our goals. The success of our Stockton facility operating at full capacity, the expansion of our renowned brands, and the remarkable growth of our Redwood City retail store are all testament to our dedication to delivering value to our customers and shareholders. We are proud of the strides we've made, and we remain focused on leading the way in the evolving cannabis industry.”

In other news, the Company also granted 19,250,000 stock options to directors, officers, employees, and consultants.  The stock options are exercisable at $0.045 per stock option and expire 10 years from the date of grant.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company is leveraging multi-disciplinary research experts across various fields standardization of cultivation, extraction, and formulation to offer consumers reproducible medical benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology through a validated discovery technology platform. The Company will leverage revenue derived from its retail operations to advance JUVA-019, JUVA-041, and other potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Juva is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

###

 

 


Juva Life Announces Grand Opening of Redwood City Retail Cannabis Storefront

Juva Life Announces Grand Opening of Redwood City Retail Cannabis Storefront

Redwood City, California – July 24th 2023 - Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to announce the highly anticipated Grand Opening of its retail cannabis store in Redwood City, California. This news follows the previously announced soft opening that occurred as planned on June 23rd, 2023. The Grand Opening ceremony is scheduled to take place on July 27th, 2023 at 9:00am PDT and marks a significant milestone in Juva Life's commitment to providing high-quality cannabis products and exceptional customer experiences.

"We are thrilled to invite the community to join us for the Grand Opening of our Redwood City retail store. This event represents a culmination of our vision to create a premier destination for cannabis enthusiasts and those seeking wellness through cannabis," said Doug Chloupek, CEO and Founder of Juva Life. "We have diligently crafted a modern retail environment that combines expertise, education, and a diverse product selection to cater to the needs and preferences of our community in a space that is open and inviting."

Located in Downtown Redwood City at 2301 Broadway Street, the Juva’s retail store offers a wide range of premium cannabis products, including flower, edibles, concentrates, and topicals. Customers can expect a thoughtfully curated selection that reflects Juva's commitment to quality, consistency, and innovation. Included in the inventory will be all products from The Company’s brands, including Frosted Flowers, Flōs, and Secret Sauce. The knowledgeable and friendly staff will be available to provide personalized recommendations and ensure a safe and enjoyable shopping experience. The store also features an interactive art installation as its centerpiece.

With the Grand Opening, the Company aims to showcase its dedication to community engagement, wellness education, and responsible cannabis consumption. Attendees will have the chance to explore the diverse product offerings, learn about the latest cannabis trends, and discover the potential benefits of cannabis for personal well-being. The event will feature promotions and opportunities to connect with industry experts, city officials, and local influencers.

When asked about Juva’s storefront opening, Redwood City’s Mayor, Jeff Gee said, "We welcome and are excited for the Grand Opening of Juva's retail cannabis store in our Downtown. Juva has been a valuable partner in our community since opening their cannabis delivery service in early 2020. We look forward to continuing our relationship and are delighted that they have decided to open a storefront in Redwood City. Their commitment to quality, compliance, and responsible commercial cannabis activity aligns with our shared vision of promoting a thriving and inclusive local economy that serves everyone.”

"The Grand Opening of Juva Life's retail cannabis store is a momentous occasion for Redwood City,” said Regina Van Brunt of Redwood City’s Downtown Business Group, “and we are thrilled to welcome Juva into our downtown core.  For the last 3 years Juva has been a great partner to the Downtown Business Group, donating both their time and money to support the local community. We anticipate that Juva’s commitment to our community, their exceptional customer service, and their diverse selection of high-quality cannabis products will further enhance the vibrant atmosphere and economic vitality of our downtown district."

"We look forward to celebrating this milestone with the community of Redwood City and surrounding areas. Our goal is to foster a welcoming environment where individuals can explore and experience the benefits of cannabis in a responsible and informed manner," added Doug Chloupek.

The Company remains dedicated to promoting responsible cannabis use and contributing positively to the communities it serves.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company is leveraging multi-disciplinary research experts across various fields standardization of cultivation, extraction, and formulation to offer consumers reproducible medical benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology through a validated discovery technology platform. The Company will leverage revenue derived from its retail operations to advance JUVA-019, JUVA-041, and other potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Juva is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

###

 

 


Juva Life Announces Completion of Construction on Redwood City Retail Cannabis Storefront and Soft Opening Date

Juva Life Announces Completion of Construction on Redwood City Retail Cannabis Storefront and Soft Opening Date

Redwood City, California – June 21st, 2023 - Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is pleased to announce the completion of construction on its highly anticipated retail cannabis store in Redwood City, California. The Company is now preparing for its soft opening scheduled for June 23rd, 2023.

"We are thrilled to announce that construction on our Redwood City retail location has been successfully completed. Our team has worked diligently to create a beautiful cannabis storefront that will provide an exceptional customer experience," stated Doug Chloupek, CEO and Founder of Juva Life. "As the highest-scoring applicant during the permitting process, we are proud to have been awarded a permit to operate a retail cannabis business in Redwood City. This milestone allows us to expand our presence and strengthen our connection with the local community."

The new retail store is located in Downtown Redwood City, at 2301 Broadway Street, and will offer a wide range of premium cannabis products to adult consumers. Customers can expect a curated selection of high-quality products, expert staff, and a welcoming atmosphere designed to enhance their cannabis shopping experience. Juva Life’s existing delivery operations are being consolidated into the new retail store, allowing for operational efficiencies and cost savings.

Redwood City's retail cannabis program was developed in collaboration with community support after the state's legalization of adult-use cannabis sales in 2018. In addition, Juva Life was the highest-scoring applicant during the permitting process, highlighting the Company's commitment to excellence and regulatory compliance.

Juva Life continues to focus on pharmaceutical research and cannabis science. The Company's ongoing efforts include the advancement of JUVA-019 and JUVA-041, two promising compounds that are currently undergoing preclinical in vivo trials. These research endeavors aim to unlock the potential therapeutic applications and benefits of the cannabis plant.

"We remain dedicated to our dual-pronged approach, combining our consumer-facing operations with cutting-edge pharmaceutical research. Our commitment to scientific discovery and our mission to understand the potential benefits of cannabis is unwavering," said Doug Chloupek, emphasizing the Company's focus on driving innovation and growth in the industry.

The Company is pleased to announce that it issued convertible unsecured notes to JLL Ventures Inc. and JT Labs LLC (together, the “Holders”) for CAD$2,230,400 bearing interest at 30% per annum due and payable on December 1, 2024 (the “Note”).  In the event of default or non-payment, the Note is convertible into common shares of the Issuer by dividing (i) the Converted Amount and (ii) the Conversion Price then in effect, rounded down to the nearest whole number of shares.  Related to this relationship, the Company is also issuing a total of 2,186,666 warrants to these parties and another entity, each convertible into one share of the Company, exercisable at $0.054 per warrant until June 1, 2028.

The Company would also like to announce that on June 5, 2023, 17,220,000 stock options were canceled.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company is leveraging multi-disciplinary research experts across various fields standardization of cultivation, extraction, and formulation to offer consumers reproducible medical benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology through a validated discovery technology platform. The Company will leverage revenue derived from its retail operations to advance JUVA-019, JUVA-041, and other potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Juva is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

###

 

 


Juva Life Begins Construction on Redwood City Retail Storefront, On Track to Open in Early 2023

Juva Life Begins Construction on Redwood City Retail Storefront, On Track to Open in Early 2023

Company Was Previously the Highest-Scoring Applicant During the Permitting Process in Redwood City, California

VANCOUVER, British Columbia, November 8, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today that the Company has started construction on their upcoming Redwood City, CA retail location. The retail cannabis storefront is expected to open for business in Q1 2023 in Downtown Redwood City, California, at 2301 Broadway Street.

“Starting construction of our Redwood City Retail location is an exciting process, and we are on track to open our doors in early 2023. Juva has proudly been delivering products for nearly 2.5 years in Redwood City and the surrounding areas, and we are excited to open our first cannabis brick and mortar retail store,” said Doug Chloupek, CEO and Founder of Juva Life. “Juva was the first operational cannabis delivery company in Redwood City and we expect to be the first retail store as well; we look forward to further solidifying our presence and making deeper connections with our customers in this region.”

Redwood City, California, has a retail cannabis program that was developed hand-in-hand with community support following the state’s legalization of adult-use cannabis sales in 2018. As previously announced on April 6, 2022, Juva was granted one of only four approvals within Redwood City, allowing storefront retail cannabis businesses in commercial and mixed-use zones. The process included a merit-based application to ensure high-quality retail cannabis business operators would be thoroughly reviewed and sufficiently qualified before receiving a permit. Juva Retail RWC Inc. was the highest-scoring applicant overall, being awarded a total of 1,876 points in Phase III, which, when combined with the Company’s Phase II score of 1,196 points, equals 3,072 points for a total score of 96%.

Additionally, Juva Life continues its dual-pronged approach to its business, with the other side of operations consisting of pharmaceutical research and rigorous cannabis science to unlock the secrets behind the cannabis plant’s anecdotal benefits. Juva continues discovery efforts to identify new compounds and advance JUVA-041 through industry standard pre-clinical inflammatory models and non-clinical tests enabling IND filing. Beyond its clinical research programs, Juva also recently relaunched its WIRB-approved JuLi Registry study with the goal of cultivating one of the largest data sets on the medicinal applications of cannabis use to exist to date.

 

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

Investor Relations:
Kyle Porter
858.221.8001
juva@cmwmedia.com

Corporate Contact:
1.833.333.JUVA (5882)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

###

 

 


Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process

Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process

Company Reports Successful Medicinal Chemistry Effort to Scale Up Small Molecule Isolated from Cannabis Plant to Support Preclinical and Non-Clinical Studies

VANCOUVER, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today announced the successful scale up of promising proprietary molecule, JUVA-041, from microgram quantity to 5 gram quantity. The Company’s approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry, and a large commercial advantage. This strategy will not only allow for the identification of new compositions of matter, but ones that are scalable and affordable.

“Novel compound Juva-041 has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, and is now being scaled up to support pre-clinical studies,” said Doug Chloupek, CEO and Founder of Juva. “Through Juva’s proprietary platform, we have made significant developments identifying the method and mode of action behind cannabis’ anecdotal therapeutic potential. This scale-up hurdle we have crossed allows us a straight shot for commercial development devoid of manufacturing obstacles. These studies are the next step in unlocking the hidden value of the cannabis plant. Many companies struggle to scale up at the speed that Juva has, we are very pleased to see our alternative approach to medicinal chemistry is proving to be our competitive advantage.”

To date, one of the most significant challenges companies face is the scale up of starting material and creation of finished drug products to support the FDA required non-clinical studies. This has significantly hampered existing pharmaceutical and consumer approaches. Juva has discovered novel compounds JUVA-019 and JUVA-041 that have shown superior anti-inflammatory drug properties compared to many commercially available products. This provides Juva a significant development and commercial advantage as the speed of learning and cost of development is significantly less than established pharmaceutical approaches.

JUVA-041 is a small molecule isolated from cannabis uniquely identified by Juva Life’s research team. As with previously announced JUVA-019 (announced Jan. 6, 2022), JUVA-041 inhibits key cytokines proven to be of clinical relevance in inflammation but does so with selectivity and increased potency. Through the identification of JUVA-041, the Company now has demonstrated the efficiency of its discovery approach, in uncovering a second small molecule from cannabis with bona fide anti-inflammatory properties. The Company believes that the observed clinical effects of cannabis are coupled to small molecules with selective anti-inflammatory properties.

The scale up of JUVA-041 through the standard pharmaceutical stage gate process, from microgram quantities to 5 gram quantities, will enable researchers to continue to test efficacy and toxicity of the molecule in mouse models. JUVA-041 has a pending patent filed by Juva Life and was identified by Juva’s chemistry researcher through a chemocentric approach to bioactive identifications.

Juva continues its discovery efforts to identify new leads and advance JUVA-041 through industry standard pre-clinical inflammatory models and non-clinical tests enabling IND filing. Beyond its clinical research programs, Juva also recently relaunched its WIRB-approved JuLi Registry study with the goal of cultivating one of the largest data sets on the medicinal applications of cannabis use to exist to date.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Investor Relations:
Kyle Porter
858.221.8001
juva@cmwmedia.com

Corporate Contact:
1.833.333.JUVA (5882)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Announces Flōs, New Branded Cannabis Flower Product Line

Juva Life Announces Flōs, New Branded Cannabis Flower Product Line

New Branded Cannabis Product Line Diversifies Company Product Offerings; Compliments Pharmaceutical Research

VANCOUVER, British Columbia, September 21, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s new product line, Flōs, a branded line of flower and pre-rolled cannabis products.

“Our Flōs line provides consumers with high-quality cannabis products without paying top shelf prices, and further expands our product category to capitalize on the massive market growth within California,” said Doug Chloupek, CEO and Founder of Juva. “We’re thrilled that the completion of our Stockton cultivation facility construction has doubled our output capacity, creating space for us to offer new consumer packaged goods that our customers are requesting.”

Flōs is Latin for blossom, or flower, and the unique beauty of the cannabis flower is on full display with Juva’s new product line. Featuring eighth ounce quantities, pre-rolls in one gram quantity, and half ounces of flower products, these meticulously-selected cultivars are budget-friendly without sacrificing quality.

The Flōs flower line is available for distribution throughout the entire state of California, and is also available through Juva Delivery, which is a division of vertically integrated Juva Life, Inc. Juva Delivery also offers contactless pre-payment options through Paytender, a secure, fee-free online payment service. The Flōs flower line will also be featured in the future at the Company’s upcoming retail store, which has been approved for licensing by the City of Redwood City, and is currently under construction.

Each Flōs product begins with the highest quality cannabis cultivars grown at the Company’s 30,000-square-foot Stockton, California, cannabis cultivation facility. Once harvested and cured, the material is then moved to Juva’s distribution division for final processing and statewide distribution. To find available products locally in the San Francisco Peninsula area, visit here.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release


Juva Life Reports 144% Increase in Revenue for Q2 2022; Schedules Webinar for 9/6/22

Juva Life Reports 144% Increase in Revenue for Q2 2022; Schedules Webinar for 9/6/22

Company Reports Its Q2 2022 Financial Results and Provides Comments on Operations

VANCOUVER, British Columbia, August 31, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today highlights its financial and operating results for Q2 of 2022, and announces an upcoming webinar to review results and provide operational updates.

The Company generated $1.8 million of revenue in Q2 2022, a 144% increase over the same period in the previous year. For the six-month period ending June 30, 2022, the Company generated $2.9 million in revenue, a 123% increase from the same period in the previous year. This growth was driven by increased sales in both its retail delivery business as well as sales of wholesale bulk cannabis flower cultivated at the Company’s recently expanded  facility in Stockton, CA. Additionally, net loss for the quarter decreased from $2.8 million in Q2 2021 to $1.9 million in Q2 2022, pointing to a positive trend in cost-reduction and healthy growth. The Company also completed an $11.8M financing in Q2 that allowed for the purchase of its Stockton facility,  capitalizing on the $10M+ in previous leasehold improvements, and strengthening its cash balance. The additional funds will allow for expansion of both its cannabis operations and research programs.

Operationally, in the second quarter of 2022, Juva continued its preclinical research program on novel compound Juva-041. The compound, which has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, is currently being scaled up to support pre-clinical and non-clinical pharma development studies. Beyond its clinical research programs, Juva also relaunched its WIRB-approved JuLi Registry study with the goal of cultivating one of the largest data sets on the medicinal applications of cannabis use to exist to date.

Through its cannabis operations, the Company completed multiple milestones including the launch of in-house brands `Secret Sauce” and “Flos.” It also received local provisional licensing of its cannabis retail storefront location in Redwood City. The Company received an industry-leading, almost perfect score in its application review and is about to begin construction on the facility, with the application for State licensing concurrently under review.

“I could not be more excited by the momentum Juva is experiencing in both its cannabis operations and clinical research,” said Doug Chloupek, CEO and Founder of Juva. “While many of our industry peers in California are struggling to expand their businesses, or even survive, Juva is experiencing quarter-over-quarter growth in revenue, while we continue to cut costs and increase margins. As we continue the permitting of our upcoming Redwood City retail location, we will further optimize our Stockton facility, where we continue to increase yield with minimal additional costs. On the pharmaceutical research side, we continue to move at an unprecedented pace in proving the therapeutic potential of our novel compound, Juva-041. All said, I believe we are heading in a positive direction as an organization and I look forward to updating the market during our webinar next week!”

The Company has scheduled a webinar hosted by Chief Executive Officer Doug Chloupek at 4:30pm ET on September 6th, 2022. On the webinar Doug, along with other team members from the Company, will present in greater detail on the results from the second-quarter and first half of 2022, as well as where the company is headed throughout the remainder of the year. The webinar will also include a Question and Answer session. Anyone interested in submitting questions are asked to send them to Juva@cmwmedia.com by 5pm EST on September 1st.

 

Those interested in attending the webinar can register here: https://zoom.us/webinar/register/WN_alOR1mE3TwKVqhnOgC7sVQ

 

The webinar will be available for viewing on the Company’s website 24 hours after its airing.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Media Relations:
Kyle Porter
858.221.8001
juva@cmwmedia.com

Corporate Contact:
1.833.333.JUVA (5882)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Launches Revised JuLi Registry, Showcases Cannabis and CBD Brands to Track Effects on Cannabis Patients

Juva Life Launches Revised JuLi Registry, Showcases Cannabis and CBD Brands to Track Effects on Cannabis Patients

Life Science Research and Vertically Integrated California Cultivator Creates Global Research Registry to Better Understand Clinical Effects of Cannabis

VANCOUVER, British Columbia, August 16, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today announced their newly revised WCG IRB-approved cannabis patient registry, renamed to the JuLi Registry (“The Registry”).

The JuLi Registry is a WCG IRB -approved multi-year study conducted through Juva Life’s cannabis research division. The Registry, listed on clinicaltrials.gov, is aimed at amassing one of the world’s largest data sets of real-world clinical evidence on the potential health benefits of cannabis. It enjoys participation from best-in-class cannabis and cannabidiol (CBD) brands, and includes products from CannaCraft, dosist, LEVEL, San Benito Hemp Company, Sunderstorm, and WYLD.

Once completed, Juva will have one of the largest data sets of its kind and will be able to leverage the findings in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and other clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.

“The Juli Registry will amass one of the largest repositories of real-world data of its kind, tracking the medicinal effects of cannabis use, which few companies globally are seeking to create,” said Doug Chloupek, CEO and Founder of Juva. “Thanks to the participation of our world-class brands, cannabis patients nationwide can track the effectiveness of a broad selection of curated products which may help individual participants and researchers better understand clinical benefits from specific products and dosing schedules. The data we collect is kept confidential, and this study is crucial in understanding the medicinal benefits of cannabis-based products through real-world data gathering.”

“The cannabis plant has such remarkable therapeutic promise. Yet research has been stymied for decades by federal restrictions,” says Tiffany Devitt, Chief of Regulatory Affairs for CannaCraft. “We're thrilled that Juva is taking the initiative to creatively work around restrictions and essentially crowd-sourcing data from the millions of people using this long-standing herbal remedy.”

"Since inception, dosist has been a pioneer in the study of cannabinoids and their positive clinical effect for consumers," stated Jason DeLand, Executive Chairman and Co-Founder of dosist.  "Precise dosage, exact formulations and maximum bioavailability are paramount to creating a consistent, repeatable experience that engenders consumer trust, and we applaud Juva's efforts to further confirm and elevate the targeted usage and wellness benefits of this amazing plant."

“Cannabinoids have a myriad of therapeutic properties, and we’re just starting to define their positive impact on human health,” said LEVEL Founder and CEO Chris Emerson, PhD. “At LEVEL, we’re dedicated to conducting research, pushing the scientific boundaries, and driving consumer education about cannabinoids, which facilitates our unique approach to developing innovative cannabis products. Leveraging real-world clinical evidence on the potential health benefits of cannabis will shape the future of the industry, and LEVEL is excited to participate in this important work.”

“We find it our duty to help showcase what this amazing plant is really capable of,” says Matthew Mielczarek, CEO and Co-Founder of San Benito Hemp Company. “The cannabis plant has so many uses, we have only begun to scratch the surface of its medicinal qualities. We are extremely excited to be working with Juva on this groundbreaking study that will not only enlighten all of our understandings of the cannabis plant but help guide us for future growth.”

"At Sunderstorm, wellness has been the foundation of everything we do, leading to the development of our Tranquility gummy which was scientifically designed to assist in sleep-related issues,” said Cameron Clark, CEO and Co-Founder of Sunderstorm. “We are proud to support Juva’s efforts to further validate the health benefits and efficacy of our Tranquility product and cannabis products within the industry at large."

The goal of the Registry is to collect data on cannabis formulations, chemical composition, dosing and utilization, and the effectiveness of cannabis products in addressing designated medical concerns. The study is open to patients over 21 years of age who have the following conditions or symptoms: chronic pain, anxiety, neuropathy, appetite issues, nausea, sleep issues, and menopausal symptoms. Info on products selected, dosing schedules, impact on symptoms and side effects will be collected. Additionally, the Registry will examine patients’ use of cannabis in conjunction with other prescription medication, including any discontinuation or reduction of the use of opioids after initiation of cannabis-based medications. Learn more and sign up for the JuLi Registry here: https://juvaresearch.com/the-juli-registry/

About CannaCraft

CannaCraft is a vertically-integrated company, founded in 2014 with the mission to produce safe and effective cannabis products. The company currently manufactures and distributes AbsoluteXtracts, Care By Design, Lagunitas Hi-Fi Sessions, Farmer & The Felon, and Loud+Clear from their licensed facilities in Santa Rosa, California. CannaCraft’s product portfolio boasts hundreds of unique products, including vape cartridges, tinctures,

topicals, soft gels, packaged flower, gummies, concentrates, and beverages. Learn more at www.cannacraft.com.

About dosist

dosistTM, based in Los Angeles, California, launched in 2016 and has since become known as a disruptor in both the cannabis and health & wellness industries. dosist was named one of Time Magazine's Best Inventions, recognized by Fast Company as one of the Top 10 Most Innovative Companies in the health sector, and designated by LinkedIn as the number two Top Startups: Hottest U.S. Companies To Work For Now. dosist provides elevated consumer benefits and cannabinoid experiences through their regulated THC business featuring the best cannabis delivery systems and formulas in the vaporization and ingestible markets, and through their dosist health business, launched in late November 2020, expanding the company’s reach across the wellness sector with a new range of CBD+ formulas and products available through its direct-to-consumer platform and at key retailers nationwide. For more information about dosist visit dosist.com and dosisthealth.com.

About LEVEL

LEVEL is a science-driven cannabis company at the forefront of cannabinoid research and innovation that is passionate about helping to guide humans with the information and products they need to make informed decisions and take action. We launched LEVEL with one goal in mind: to create unique, targeted, effects-based cannabis products by formulating cannabinoids in ratios inaccessible from the plant alone.

About Sunderstorm
Established in California in 2015, Sunderstorm is one of the largest and most trusted manufacturers of cannabis products, currently serving the California, Nevada, Massachusetts, Colorado and Canadian markets. Their mission is to help people achieve a life of harmony and wellness with all-natural, consciously made, science-based cannabis products. Widely considered the best tasting gummy in the industry and the 4th-largest edible brand in the U.S., Sunderstorm's award-winning Kanha premium gummies are made with the highest-quality cannabis oils, scientifically extracted and infused to provide a consistent dose.

About San Benito Hemp Company

Since launching in 2019, San Benito Hemp Company has pioneered a unique true solventless process using cutting edge technology to produce efficacious hemp products for a growing global market. Our mission is to promote wellness by offering the best and most dependable supply of Absolute-grade CBD extracts on the market. Our Absolute extraction process is optimized to capture the broadest spectrum of hemp compounds resulting in therapeutically-rich, high-grade products that embody the principles of wellness, balance and sustainability.

To learn more about the JuLi Registry, please visit: https://juvaresearch.com/juli-registry-faq/

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company is leveraging multi-disciplinary research experts across various fields standardization of cultivation, extraction, and formulation to offer consumers reproducible medical benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology through a validated discovery technology platform. The Company will leverage revenue derived from its retail operations to advance JUVA-019, JUVA-041, and other potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Juva is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

Investor Relations:
Kyle Porter
858.221.8001
juva@cmwmedia.com

Corporate Contact:
1.833.333.JUVA (5882)

 

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Highlights Q1 2022 Financials Showing 97% Increase in Revenue

Juva Life Highlights Q1 2022 Financials Showing 97% Increase in Revenue 

Company Reports Its Q1 2022 Results and Provides Comments on Operations

VANCOUVER, British Columbia, July 19, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today highlights its financial and operating results for Q1 of 2022.

$1.16 million of revenue was generated in  Q1 2022, almost double the $.58 million of revenue in the same period for the prior year. This growth was driven by increased sales in both its retail business operations as well as sales of wholesale bulk cannabis flower. Net loss for the quarter decreased from $5.5 million in Q1 2021 to $3 million in Q1 2022.

In the first quarter of 2022, Juva advanced JUVA-019, a proprietary novel compound that has previously demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, from discovery into preclinical development. It also advanced JUVA-041, a second proprietary novel compound into preclinical development, further substantiating the Company’s discovery strategy and technology platform. Juva Life has filed patents on both compounds and plans to advance them through the standardized clinical stage gate in the coming months. Also on the clinical side of the Company, Juva launched the Journal App that offers cannabis users a daily tracking solution to monitor how their cannabis consumption affects their personal health and wellness, furthering Juva’s mission of proving the therapeutic value of cannabis.

Additionally, the Company completed the final phase of construction of its 30,000-square-foot Stockton cultivation facility, which more than doubled the growing capacity of the facility without adding additional costs, and maximizing the facility’s cultivation systems. 

“As we move to the second half of the year, we are feeling extremely confident about our progress in both our life sciences research and cannabis operations,” said Doug Chloupek, CEO and Founder of Juva. “Our research team is moving at an unparalleled pace in proving the potential therapeutic value of both of our lead candidates, JUVA-019 and JUVA-041. We have already seen extremely promising preclinical results in their ability to inhibit inflammation, and we are moving them forward in their clinical pipeline as quickly as possible. On the cannabis operations side, our cultivation facility in Stockton is fully complete and firing on every cylinder. The delivery business is continuing to grow, and we are so excited to have received one of the first and only retail licenses in Redwood City. All in all, Q1 was a great first quarter for Juva, and we are looking forward to sharing our Q2 results in short order.” 

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Investor Relations:
Kyle Porter
858.221.8001
juva@cmwmedia.com

Corporate Contact:
1.833.333.JUVA (5882)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.